Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort

Date

02 Dec 2023

Session

Poster Display

Presenters

Yan Yu

Citation

Annals of Oncology (2023) 34 (suppl_4): S1661-S1706. 10.1016/annonc/annonc1391

Authors

Y. Cheng1, Y. Yu2, Y. Fan3, L. Jiang4, L. Wu5, J. Hu6, J. Wang7, W. Yao8, Z. Han9, Y. Yao10, J. Fang11, M. Sun12, Q. Wang13, Y. Pan14, R. Wu15, J. Liu16, Y. Liu17, D. Kulkarni18, X. Huang19, P.A. Jänne20

Author affiliations

  • 1 Department Of Thoracic Oncology, Jilin Cancer Hospital, 130021 - Changchun/CN
  • 2 Department Of Medical Oncology, 3rd Affiliated Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 3 Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou/CN
  • 4 Department Of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 5 Thoracic Medical Oncology, Hunan Province Tumor Hospital, Changsha/CN
  • 6 Department Of Respiratory And Critical Care Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai/CN
  • 7 Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai/CN
  • 8 Medical Oncology, Sichuan Cancer Hospital, Chengdu/CN
  • 9 Thoracic Oncology, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi/CN
  • 10 Medical Oncology, The First Affiliated Hospital of Xian Jiaotong University, Xian/CN
  • 11 Thoracic Oncology, Beijing Cancer Hospital, Beijing/CN
  • 12 Department Of Oncology, Jinan Central Hospital, Shandong University; Central Hospital Affiliated to Shandong First Medical University, Jinan/CN
  • 13 Department Of Internal Medicine, Affliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, ZhengZhou/CN
  • 14 Medical Oncology, Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology, Hefei/CN
  • 15 Medical Oncology, Sheng Jing Hospital, Shenyang/CN
  • 16 Department Of Oncology R&d, AstraZeneca, Beijing/CN
  • 17 Biometrics, R&D China, AstraZeneca, Shanghai/CN
  • 18 Late Development Oncology, AstraZeneca, Cambridge/GB
  • 19 Oncology Biometrics, AstraZeneca, Cambridge/GB
  • 20 Department Of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 562P

Background

Osi is a third-generation, CNS active EGFR-TKI. The primary analysis of the global, phase III, open-label, randomised FLAURA2 (NCT04035486) study in pts with EGFRm advanced NSCLC demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with 1L osi + chemotherapy (osi + CT) vs osi monotherapy (osi-mono). We report data of pts in China from FLAURA2.

Methods

Eligible pts (aged ≥18 yrs with locally advanced/metastatic EGFRm [Ex19del/L858R] NSCLC, WHO PS 0/1 and no prior systemic treatment [tx] for advanced NSCLC; stable CNS metastases allowed) were randomised 1:1 to osi + CT (osi 80 mg QD + pemetrexed [pem] 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC5 Q3W for 4 cycles, followed by osi 80 mg QD + pem 500 mg/m2 Q3W) or osi-mono (80 mg QD) until progression/discontinuation criterion; stratified by race (Chinese Asian/non-Chinese Asian/non-Asian), EGFR mutation test method (local/central) and WHO PS (0/1). Primary endpoint: PFS by investigator assessment. Secondary endpoints included OS, ORR, DoR and safety. Data cut-off: 03 April 2023.

Results

Overall, 131 pts in China were randomised to osi + CT (n=67) or osi-mono (n=64). Baseline characteristics (osi + CT/osi-mono) were: median age (range), 61 (42–74)/60 (32–78) yrs; 63/59% female; 48/59% Ex19del; 51/39% L858R (1 unknown EGFR mutation type per arm); 51/42% CNS metastases. Osi + CT improved PFS vs osi-mono (49% maturity by investigator; Table). OS was immature (21% maturity); HR 0.97 (95% CI 0.45, 2.06). All grade ≥3 AEs (osi + CT/osi-mono): 75% (mainly haematological)/26%; AEs leading to osi discontinuation: 3/5%.

Conclusions

In the China cohort, osi + CT demonstrated a clinically meaningful improvement in PFS over osi-mono with a manageable safety/tolerability profile consistent with the global study population, supporting osi + platinum-pem as a new 1L tx option for pts in China with advanced EGFRm NSCLC. Table: 562P

Efficacy output Osi + CT (n=67) Osi-mono (n=64)
Median PFS by investigator, months (95% CI) 27.4 (22.3, NC) 22.3 (16.7, 25.0)
HR (95% CI) 0.56 (0.34, 0.92)
Median follow-up for PFS, months (range)* 22.3 (0–30.6) 23.7 (3.0–33.1)
Median PFS by BICR, months (95% CI) 33.2 (25.1, NC) 22.0 (16.6, NC)
HR (95% CI) 0.58 (0.34, 1.01)
Median follow-up for PFS, months (range)* 24.2 (0–30.5) 22.3 (3.0–33.2)
ORR by investigator, n (%) 58 (87) 49 (77)
Median DoR by investigator, months (95% CI) 26.2 (20.7, NC) 20.8 (15.3, 23.5)

∗In censored pts.BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; HR, hazard ratio; NC, not calculable; NR, not reached; ORR, objective response rate

Clinical trial identification

FLAURA2: NCT04035486.

Editorial acknowledgement

The authors would like to acknowledge Rachel Gater, Ph.D., of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

L. Jiang: Non-Financial Interests, Personal, Local PI: Shanghai Chest Hospital, Shanghai Jiao Tong University, PR China. J. Liu, Y. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. D. Kulkarni, X. Huang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyte, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other: Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Royalties: Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.